Lipidica, a.s.’s Post

Kidney Cancer Drugs Market: A Domain of Gazillion Opportunities A data published by the American Cancer Society; kidney cancer is one of the 10 most common cancers in 10 common cancers in both women and men in the United States. By Aashi Mishra, Research Writer at Research Nester Analytics Read More...https://lnkd.in/gjS5hqQj #medhealthreview #researchnester

🎗 #PancreaticCancer: where progress meets urgency With its 5-year survival rate rising from 3% to 12%, pancreatic cancer (PC) still battles the odds as one of the deadliest cancers. 📊 Despite advances, challenges persist due to the complexity of cancer cell behavior and their interplay with the microenvironment. Here’s where it gets interesting: Necroptosis, a unique form of programmed cell death, is emerging as a key focus in unraveling PC progression. In Dr. Valentina Giansante et al's review, they dive into the historical background of necroptosis and tackle the ongoing debate—does necroptosis fuel or fight pancreatic cancer? 📖 Read the full review to explore: https://brnw.ch/21wOLOG Università degli Studi "G. d'Annunzio" Chieti - Pescara #CancerResearch #Therapeutics

Did you know that even if a cure for your cancer isn’t currently possible, comprehensive genomic profiling (CGP) and treatment matching can offer valuable opportunities to optimise your treatment plan, reduce side effects, manage symptoms and potentially extend your life? Matthew was just 24 years old when diagnosed with an advanced soft tissue cancer that compressed his spine and metastasised throughout his body. He found hope with CGP and treatment matching through Omico. He shares how CGP provided insight for a personalised treatment plan that provided an alternative for the future. To see if your eligible for free CGP with Omico, download the patient information booklet to have as a handy resource when you speak to your cancer doctor (oncologist): https://bit.ly/3XHYdTk You can also hear Matthew’s inspiring story and discover the impact of CGP and targeted treatment by visiting: https://lnkd.in/g8XM4XRd #Omico #CancerMeetsItsMatch #CGP #ComprehensiveGenomicProfiling #MeetThePeopleThatMatched

Were you at the launch of the 9th LuCE Report last week? We held a virtual launch of our latest research which is entitled ‘Empowering voices: knowledge and decision-making among people impacted by lung cancer in Europe’. The launch event brought together voices from the European Parliament, clinical experts, patients and caregivers to discuss the state of knowledge and shared decision-making in lung cancer care across Europe. We have now made the launch available to view on our YouTube channel: https://lnkd.in/e6vUDsvy #LungCancerEurope #LuCE #AnnualReport #LuCEReport #LungCancer #LungCancerAwareness #LungCancerAwarenessMonth #LCSM #cancer #LCAM #LCAM24 #LCAM2024 #LungCancerAwareness #LungHealth #EarlyDetection #CancerSupport #CancerResearch #BreatheEasy

The Laekna team will be at #ESMO next week to present clinical data on the phase Ib study of LAE002(afuresertib)+fulvestrant in HR+/HER2-breast cancer. Please connect with Chris Lu Guy Rosenthal to learn more about our innovative programs and clinical progress! #ESMOCongress2024 #AKTInhibitor #BreastCancer #DrugDevelopment #ClinicalResearch Presentation details are as follows👇 Abstract Title: A Phase Ib Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Subjects with Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care Therapies: A Subgroup Analysis of Efficacy in PIK3CA/AKT1/PTEN-Altered Subjects Final Publication Number: 370P Presentation Date: 16th Sep Venue: Hall 6

The advancements in research and treatment since the discovery of EGFR+ mutations 20 years ago have been a true global effort. From groundbreaking work in the US and Japan to innovative clinical trials in the UK, China, Australia, Canada and beyond, researchers around the world have collaborated to transform treatment options and bring new possibilities for EGFR+ lung cancer patients. #EGFR #LungCancer #CancerResearch

🚀 Aspyre Lung Speeds Up NSCLC Trials! 🚀 Aspyre Lung is accelerating non-small cell lung cancer (NSCLC) trials with innovative approaches to bring life-changing therapies to patients faster. 🧬 This advancement marks a significant step in cancer research and treatment development. 🩺 Biofidelity, CellCarta Sam Obermeyer, Karla Gonye, MBA, Nathalie Bernard, Stéphanie Bussières-Marmen, PhD Know complete story - https://lnkd.in/dRDsxjwB #AspyreLung #NSCLC #CancerResearch #PharmaInnovation #HealthcareAdvancements #FasterTrials

What are the 5 significant values of CRC screening? 🤔 Learn from Prof. Guiying Wang as she presents the Colorectal Cancer Screening and Early Diagnosis in China. Join us on the Global Cancer Movement: Challenging the Status Quo! https://lnkd.in/dNgP7N6U #Cancer #CancerResearch #ColorectalCancer #GlobalCancerMovement #CancerScreening #Screening #EarlyDetection #CancerDiagnosis #China #Medicine #Health #Oncology #OncoDaily

Family history is crucial in determining your risk for certain diseases, including lung cancer. Join us on June 29 to learn about small-cell lung cancer, risk factors, and treatments. Don't miss this important program - register here: https://lnkd.in/eXBymUyJ. Amgen #HEAL12 #FamilyHistory #LungCancerAwareness #HealthScreenings #EarlyDetection

Do you have metastatic (stage IV)/advanced cancer? Are you a caregiver to someone with metastatic cancer? If so, we want to hear your voice! CCRAN is conducting a collaborative pan-tumor biomarker survey to address the challenges that patients face in accessing biomarker testing and comprehensive genomic profiling (CGP). The data gathered through this survey will be used to advocate for timely and equitable access to biomarker testing results, Comprehensive Genomic Profiling and thereby precision medicines that may help improve patient outcomes in Canada. ➡️ Please help us ensure the patient voice is heard by filling out the survey here before May 6, 2024: https://ow.ly/ew4s50RovTm #CCRAN #CancerSurvery #Cancercanada #CGP #Biomarkers #PrecisionMedicine